Coya Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
COYA$2.99+6.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Coya Therapeutics, Inc. | ||
| Date: August 12, 2025 | By: | /s/ Arun Swaminathan Ph.D. |
|---|---|---|
| Arun Swaminathan Ph.D. | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: August 12, 2025 | By: | /s/ David Snyder |
| David Snyder | ||
| Chief Financial Officer and Chief Operating Officer | ||
| (Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.